Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia. / Mller, Marco; Fredholm, Simon; Jensen, Mathias Ebbesen; Wörtwein, Gitta; Larsen, Julie Rask; Vilsbøll, Tina; Ødum, Niels; Fink-Jensen, Anders.
In: CNS Spectrums, Vol. 27, No. 3, 2022.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia
AU - Mller, Marco
AU - Fredholm, Simon
AU - Jensen, Mathias Ebbesen
AU - Wörtwein, Gitta
AU - Larsen, Julie Rask
AU - Vilsbøll, Tina
AU - Ødum, Niels
AU - Fink-Jensen, Anders
PY - 2022
Y1 - 2022
N2 - Objective: Treatment with antipsychotics is associated with an increased risk of type 2 diabetes mellitus (T2D), and increased levels of inflammatory biomarkers are present in patients with T2D. We previously demonstrated that the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide significantly reduced glucometabolic disturbances and body weight in prediabetic, overweight/obese schizophrenia-spectrum disorder patients treated with clozapine or olanzapine. This study aims to assess the involvement of cytokines in the therapeutic effects of liraglutide. 35 Methods: Serum concentrations of 10 cytokines (IFN-γ, TNF-α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13) from fasting prediabetic and normal glucose tolerant (NGT) patients with schizophrenia-spectrum disorders were measured using multiplexed immunoassays. Prediabetic patients were randomized to 16 weeks of treatment with liraglutide or placebo 39 and cytokines were measured again at the end of the treatment. Results: IFN-γ (1.98 vs. 1.17 pg/ml, P = 0.001), IL-4 (0.02 vs. 0.01 pg/ml, P < 0.001) and IL-6 (0.73 vs. 0.46 pg/ml, P < 0.001) were significantly higher in prediabetic (n=77) vs. NGT patients (n=31). No significant changes in cytokine levels following treatment with 4liraglutide (n=37) vs. placebo (n=40) were found. 44 Conclusion: Prediabetic vs. NGT patients with schizophrenia treated with clozapine or 4olanzapine had increased serum levels of several proinflammatory cytokines, further 4substantiating the link between inflammation and T2D. Treatment with liraglutide did not 47 affect the investigated cytokines. Further testing of these findings in larger numbers of 4individuals is needed.
AB - Objective: Treatment with antipsychotics is associated with an increased risk of type 2 diabetes mellitus (T2D), and increased levels of inflammatory biomarkers are present in patients with T2D. We previously demonstrated that the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide significantly reduced glucometabolic disturbances and body weight in prediabetic, overweight/obese schizophrenia-spectrum disorder patients treated with clozapine or olanzapine. This study aims to assess the involvement of cytokines in the therapeutic effects of liraglutide. 35 Methods: Serum concentrations of 10 cytokines (IFN-γ, TNF-α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13) from fasting prediabetic and normal glucose tolerant (NGT) patients with schizophrenia-spectrum disorders were measured using multiplexed immunoassays. Prediabetic patients were randomized to 16 weeks of treatment with liraglutide or placebo 39 and cytokines were measured again at the end of the treatment. Results: IFN-γ (1.98 vs. 1.17 pg/ml, P = 0.001), IL-4 (0.02 vs. 0.01 pg/ml, P < 0.001) and IL-6 (0.73 vs. 0.46 pg/ml, P < 0.001) were significantly higher in prediabetic (n=77) vs. NGT patients (n=31). No significant changes in cytokine levels following treatment with 4liraglutide (n=37) vs. placebo (n=40) were found. 44 Conclusion: Prediabetic vs. NGT patients with schizophrenia treated with clozapine or 4olanzapine had increased serum levels of several proinflammatory cytokines, further 4substantiating the link between inflammation and T2D. Treatment with liraglutide did not 47 affect the investigated cytokines. Further testing of these findings in larger numbers of 4individuals is needed.
KW - 50 schizophrenia
KW - Clozapine
KW - Glp-1
KW - Inflammation
KW - Liraglutide
KW - Olanzapine
KW - Prediabetes
U2 - 10.1017/S1092852920002217
DO - 10.1017/S1092852920002217
M3 - Journal article
C2 - 33308348
AN - SCOPUS:85098321399
VL - 27
JO - CNS Spectrums
JF - CNS Spectrums
SN - 1092-8529
IS - 3
ER -
ID: 254775620